EUVIMEDOdkrijte EUVIMED
Klinische Studie

Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis

D Fernández-García, M Muñoz-Torres, P Mezquita-Raya, M de la Higuera, G Alonso, R Reyes-García, A Sebastian Ochoa, M E Ruiz-Requena, J Dios Luna, F Escobar-Jiménez

Journal of Endocrinological Investigation · 2008-05 · 31 (5) · 416-421

DOI: 10.1007/bf03346385 ↗

At a glance

Klinische Studie in Journal of Endocrinological Investigation, published online on 2014-03-27. Written by D Fernández-García and 9 co-authors. Institution: Bone Metabolic Unit, Endocrinology Division, University Hospital San Cecilio Granada, RETICEF, Granada, Spain. Cited 17 times so far (Crossref); 24 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Previous in vitro studies suggest that the anti-resorptive effect of raloxifene might be mediated by changes in several cytokines involved in the bone remodeling process. In this context, the osteoprotegerin (OPG)- receptor activator of NF kappa B ligand (RANKL) system is considered a key component in the osteoclastogenesis regulation. The aim of this study was to determine the effects of raloxifene treatment on serum concentrations of OPG, receptor RANKL and its relationship with biochemical markers of bone turnover and bone mineral density (BMD) in previously untreated women with post-menopausal osteoporosis. We selected 47 post-menopausal women (mean age 63+/-7 yr) with densitometric criteria of osteoporosis. We determined at baseline, 3, 6, and 12 months anthropometric parameters, biochemical markers of bone turnover, serum levels of 25(OH) D, serum levels of OPG and RANKL. BMD (dual-energy x-ray absorptiometry) in lumbar spine (LS) femoral neck and total hip was measured at baseline and 12 months after raloxifene (60 mg/day) treatment. Serum levels of OPG decreased in the 3rd and 6th month of treatment (p

Subjects

MeSH terms (MEDLINE)

AgedBone Density Conservation AgentsCalciumFemaleHumansMiddle AgedOsteoporosis, PostmenopausalOsteoprotegerinRANK LigandRaloxifene HydrochlorideVitamin D

Substances

Bone Density Conservation AgentsOsteoprotegerinRANK LigandTNFRSF11B protein, humanVitamin DRaloxifene HydrochlorideCalcium

Authors and institutions

  • Bone Metabolic Unit, Endocrinology Division, University Hospital San Cecilio Granada, RETICEF, Granada, Spain.

Cite

APA

Fernández-García, D., Muñoz-Torres, M., Mezquita-Raya, P., de la Higuera, M., Alonso, G., Reyes-García, R., Ochoa, A. S., Ruiz-Requena, M. E., Luna, J. D., & Escobar-Jiménez, F. (2008). Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. Journal of Endocrinological Investigation, 31(5), 416-421. https://doi.org/10.1007/bf03346385

Vancouver

Fernández-García D, Muñoz-Torres M, Mezquita-Raya P, de la Higuera M, Alonso G, Reyes-García R, et al. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. Journal of Endocrinological Investigation. 2008;31(5):416-421. doi:10.1007/bf03346385

BibTeX
@article{FernndezGarca2008,
  author = {Fernández-García, D and Muñoz-Torres, M and Mezquita-Raya, P and de la Higuera, M and Alonso, G and Reyes-García, R and Ochoa, A Sebastian and Ruiz-Requena, M E and Luna, J Dios and Escobar-Jiménez, F},
  title = {Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis},
  journal = {Journal of Endocrinological Investigation},
  year = {2008},
  volume = {31},
  number = {5},
  pages = {416--421},
  doi = {10.1007/bf03346385}
}
Start for free →